Lead Product(s) : Ad-RTS-hIL-12,Cemiplimab,Veledimex
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Cantor Fitzgerald
Deal Size : $15.7 million
Deal Type : Public Offering
Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock
Details : Alaunos intends to use the net proceeds from the offering to fund the continued development of the product candidates in its pipeline, and for working capital, capital expenditures and general corporate purposes.
Product Name : Ad-RTS-hIL-12
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 29, 2022
Lead Product(s) : Ad-RTS-hIL-12,Cemiplimab,Veledimex
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Cantor Fitzgerald
Deal Size : $15.7 million
Deal Type : Public Offering
Lead Product(s) : Ad-RTS-hIL-12,Cemiplimab,Veledimex
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Interim data from the phase 2 study of Controlled IL-12 and cemiplimab combo to treat rGBM, updated interim data from the phase 1 study of Controlled IL-12 and nivolumab for rGBM, and data from phase 1/2 study of Controlled IL-12 monotherapy to treat DIP...
Product Name : Ad-RTS-hIL-12
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 19, 2020
Lead Product(s) : Ad-RTS-hIL-12,Cemiplimab,Veledimex
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FCX-013,Veledimex
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The open label, single cohort Phase 1/2 clinical trial is evaluating the safety of FCX-013 as its primary objective. Secondary objectives include assessments of fibrosis at targeted sclerotic lesions at various time points through 26 weeks post-administr...
Product Name : FCX-013
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 15, 2020
Lead Product(s) : FCX-013,Veledimex
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ad-RTS-hIL-12,Veledimex
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FDA has granted Rare Pediatric Disease Designation to Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the investigational treatment of diffuse intrinsic pontine glioma (DIPG), a lethal brain tumor occurring in the pontine region of the brain.
Product Name : Ad-RTS-hIL-12
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 14, 2020
Lead Product(s) : Ad-RTS-hIL-12,Veledimex
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ad-RTS-hIL-12,Veledimex
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The phase 1/2 trial is designed to evaluate the safety and tolerability of a single intratumoral injection of Ad-RTS-hIL-12 given with up to 14 days of oral veledimex in children with gliomas.
Product Name : Ad-RTS-hIL-12
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 07, 2020
Lead Product(s) : Ad-RTS-hIL-12,Veledimex
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ad-RTS-hIL-12,Cemiplimab,Veledimex
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ziopharm’s Controlled IL-12 platform is an investigational gene therapy designed to induce and control the production of human interleukin 12 (hIL-12), a master-regulator of the immune system.
Product Name : Ad-RTS-hIL-12
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 22, 2020
Lead Product(s) : Ad-RTS-hIL-12,Cemiplimab,Veledimex
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ad-RTS-hIL-12,Cemiplimab,Veledimex
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Longer term follow-up from Controlled IL-12 monotherapy studies reinforces encouraging median overall survival and favorable safety profile.
Product Name : Ad-RTS-hIL-12
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 29, 2020
Lead Product(s) : Ad-RTS-hIL-12,Cemiplimab,Veledimex
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ziopharm Oncology to present data on Ad-RTS-hIL-12 plus veledimex, both as monotherapy and in combination with a PD-1 inhibitor (nivolumab) for the treatment of recurrent glioblastoma.
Product Name : Ad-RTS-hIL-12
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 30, 2020